1. (a) The state department, in consultation with the Indiana board of pharmacy, the medical licensing board of Indiana, the Indiana state board of nursing, and the office of the attorney general shall develop and publish a report not later than March 1 and September 1 of each year concerning the oversight of drug compounding and the risks and benefits posed by the practice of compounding.

2. (b) The report must include the following:

   1. (1) The number and type of professional licenses issued, by license type, under which the license holder may engage in drug compounding.

   2. (2) The number of licensed facilities and practices that:

      1. (A) conduct drug compounding; or

      2. (B) handle, store, administer, dispense, distribute, or use compounded drugs in a retail or outpatient setting, including:

         1. (i) a 503A pharmacy (as described in 21 U.S.C. 353a); and

         2. (ii) a medical spa (as defined in IC 25-22.5-12.5 );

            categorized by license type. This subdivision does not include a hospital or ambulatory outpatient surgical center licensed under IC 16-21 .

   3. (3) A summary of any findings related to deficiencies or violations found by the regulating board for a facility described in subdivision (2).
   4. (4) The number of investigations conducted concerning drug compounding.
   5. (5) The number and type of disciplinary actions taken, including improper marketing, advertising, or promotion of compounding drugs or related services.
3. (c) The report required by this section must be posted on the websites of the state department and the Indiana board of pharmacy. The state department shall submit the report to the legislative council in an electronic format under IC 5-14-6 .

As added by P.L.136-2026, SEC.3.